Don’t miss the latest developments in business and finance.

Jenburkt Pharmaceuticals declines after reverse turnaround in Q1

Image
Capital Market
Last Updated : Sep 01 2017 | 12:01 AM IST

Jenburkt Pharmaceuticals fell 4.42% to Rs 414.90 at 12:21 IST on BSE after the company reported net loss of Rs 2.88 crore in Q1 June 2017, compared with net profit of Rs 1.95 crore in Q1 June 2016.

The result was announced during market hours today, 30 August 2017.

Meanwhile, the S&P BSE Sensex was up 308.50 points, or 0.98% at 31,696.89. The S&P BSE Small-Cap index was up 229.70 points, or 1.47% at 15,885.72.

On the BSE, 5,563 shares were traded on the counter so far as against the average daily volumes of 6,035 shares in the past one quarter. The stock had hit a high of Rs 439 and a low of Rs 401 so far during the day. The stock had hit a record high of Rs 572.50 on 4 November 2016 and a 52-week low of Rs 345 on 14 September 2016.

The stock had underperformed the market over the past one month till 29 August 2017, declining 13.16% compared with the Sensex's 2.85% fall. The scrip had, however, outperformed the market over the past one quarter gaining 6.93% as against the Sensex's 0.9% rise. The scrip had also outperformed the market over the past one year advancing 18.93% as against the Sensex's 12.49% rise.

The small-cap company has equity capital of Rs 4.65 crore. Face value per share is Rs 10.

Also Read

Jenburkt Pharmaceuticals' total income fell 21.4% to Rs 18.10 crore in Q1 June 2017 over Q1 June 2016.

Jenburkt Pharmaceuticals is engaged in the manufacture of pharmaceutical formulations. The company offers prescription and over-the-counter drugs.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Aug 30 2017 | 12:24 PM IST

Next Story